Actualités et Activités de MPM BioImpact

Voir l'organigramme avec ses 29 principaux dirigeants

Biographies les plus recherchées chez MPM BioImpact

• Christiana Bardon, Managing Partner
• Ansbert Gadicke, Managing Partner
• Matthew Roden, Entrepreneur Partner

Créer une alerte
pour suivre les mouvements de dirigeants chez MPM BioImpact.

MPM BioImpact a 1 642 concurrents dont Griffin Gaming Partners (Etats—Unis), BlackRock (Etats—Unis) et KKR (Etats—Unis).

Actualités en fusion/acquisition en Fond.

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publié le 3 juin 2026).
• Prime Capital Financial a acquis Access Capital Partners (publié le 2 juin 2026).
• Frazier Healthcare Partners a acquis Altruix (publié le 29 mai 2026).

Contacts en Fond

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer chez Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director chez Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director chez KKR

En savoir plus sur le secteur Fond

Derniers communiqués de presse par MPM BioImpact

• The Endpoints 11: Umoja Biopharma looks to finally break through the barriers that restrict CAR-T
• Reunion Neuroscience | Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
• Entrada Therapeutics | Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45
• Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | Cullinan Therapeutics, Inc.
• Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types - Aktis
• DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved | DBV Technologies
• Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy | Cullin
• Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
• MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner
• MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de MPM BioImpact

• MPM BioImpact sur Wikipédia, Google News & Yahoo Finance en 1-click
• MPM BioImpact sur LinkedIn, X (Twitter) & YouTube en 1-click